{"id":50407,"date":"2022-11-02T20:02:03","date_gmt":"2022-11-02T19:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/"},"modified":"2022-11-02T20:02:03","modified_gmt":"2022-11-02T19:02:03","slug":"the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/","title":{"rendered":"The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature"},"content":{"rendered":"
\n

SEATTLE–(BUSINESS WIRE)–Today, the Access to Advanced Health Institute (AAHI) announced results from a study of their new RNA vaccine against COVID-19. Preclinical studies published in NPJ Vaccines<\/i><\/a> <\/i>demonstrate the ability of AAHI\u2019s unique SARS-CoV-2 self-amplifying RNA vaccine to elicit strong antibody and T cell immunity to multiple variants of SARS-CoV-2. This next-generation approach to RNA vaccine technology combines self-amplifying RNA (saRNA) with a unique nanostructured lipid carrier (NLC) delivery vehicle containing an adjuvant, and will be harnessed to drive longer lasting, broadly-protective immunity against pandemic pathogens. AAHI\u2019s RNA vaccines can easily be freeze-dried for long-term room temperature or refrigerated stability (10+ months). The SARS-CoV-2 RNA vaccine candidate, AAHI-SC2, is currently being evaluated in liquid form in a first-in-human Phase 1 \/ 2 clinical trial sponsored by ImmunityBio in South Africa (NCT05370040<\/a>).\n<\/p>\n

<\/a><\/p>\n

\nThe current RNA vaccine strategy endorsed by the US government in response to the COVID pandemic relies on continuous development and distribution of boosters against the newest variants of concern that will likely induce protection of six months or less. This rapidly waning protection leaves high-risk populations such as the elderly, children, and immunocompromised much more vulnerable. \u201cWe clearly need vaccines against COVID-19 that drive protection for more than a few months \u2013 both in high-resource and low resource regions \u2013 to truly bring this pandemic to an end,\u201d said Emily Voigt, Principal Scientist and Manager of the RNA Vaccine Platform team at AAHI. \u201cAAHI\u2019s self-amplifying, adjuvanted RNA vaccine technology is not only easy to manufacture but has the potential to extend immune protection even in the face of an evolving virus \u2013 whether COVID-19 or the next pandemic virus.\u201d\n<\/p>\n

\nFurther complicating the world\u2019s ability to rapidly respond to pandemic threats are the low temperature requirements (-20\u00b0C and -80\u00b0C) for transportation and storage of available COVID RNA vaccines, which makes universal distribution of the current vaccines well-nigh impossible. AAHI-SC2 addresses these issues by inducing strong immune responses with a freeze-dried, also known as lyophilized, vaccine product. This lyophilized vaccine is demonstrated to be stable at standard refrigerated temperatures for at least 10 months and can be stored at room temperature for six months, as may be necessary during vaccine distribution. The improved temperature stability of AAHI-SC2 enables more equitable access to COVID RNA vaccines, especially in rural and remote communities where resources are limited.\n<\/p>\n

\n\u201cThere is still a large vaccine equity gap \u2013 prices are high, manufacturing is complex, and deep cold chain logistics are a nightmare. This gap is widening as the vaccine wanes and emerging COVID variants evade protection, requiring continuous and updated boosters. AAHI is taking a pragmatic approach to RNA vaccine development so that everyone, including people in resource limited areas, will have rapid access to long lasting and broad protection,\u201d said Corey Casper, MD, Chief Executive Officer at AAHI. \u201cOur partnership with ImmunityBio has made our commitment to bringing this next-generation RNA vaccine technology to the people who need them most, a reality.\u201d\n<\/p>\n

\nAAHI continues to optimize its immune-enhancing RNA vaccine technology for enhanced functionality and accessibility, including by investigating alternative routes of administration such as nasal spray, to stop the virus at the gate of entry to the body and to curtail transmission, and exploring the potential for a dry powder RNA vaccine.\n<\/p>\n

\nAAHI is a nonprofit biotech research institute located in Seattle, Washington that combines the high-quality science of an academic research organization with the product-development capabilities of a biotech company to help combat some of the world\u2019s deadliest diseases, including COVID-19, cancer, fungal and parasitic infections, and other non-communicable diseases. For nearly three decades, AAHI, previously known as the Infectious Disease Research Institute, has focused on creating immune-enhancing technologies that improve the body\u2019s natural response to disease. Through collaborations, AAHI brings innovation from the lab to the clinic to the people, furthering AAHI\u2019s mission to bring together the best experts, technologies, and platforms to create accessible, high-quality products and solutions. AAHI is working to build a world in which every person has access to tools that harness their immune system and allow them to live a healthy life free of illness and disease. For more information, go to AAHI.org<\/a> or follow us on LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCasey Benadof
\n
Media@aahi.org<\/a>
(206) 960-1479\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SEATTLE–(BUSINESS WIRE)–Today, the Access to Advanced Health Institute (AAHI) announced results from a study of their new RNA vaccine against COVID-19. Preclinical studies published in NPJ Vaccines demonstrate the ability of AAHI\u2019s unique SARS-CoV-2 self-amplifying RNA vaccine to elicit strong antibody and T cell immunity to multiple variants of SARS-CoV-2. This next-generation approach to RNA … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50407","6":"format-standard","7":"category-industry"},"yoast_head":"\nThe Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SEATTLE–(BUSINESS WIRE)–Today, the Access to Advanced Health Institute (AAHI) announced results from a study of their new RNA vaccine against COVID-19. Preclinical studies published in NPJ Vaccines demonstrate the ability of AAHI\u2019s unique SARS-CoV-2 self-amplifying RNA vaccine to elicit strong antibody and T cell immunity to multiple variants of SARS-CoV-2. This next-generation approach to RNA ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-02T19:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221102005965\/en\/1623204\/21\/AAHI_BrandAssets_PhotonFactory_20211201_AAHI_Logo_Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature\",\"datePublished\":\"2022-11-02T19:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\\\/\"},\"wordCount\":725,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221102005965\\\/en\\\/1623204\\\/21\\\/AAHI_BrandAssets_PhotonFactory_20211201_AAHI_Logo_Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\\\/\",\"name\":\"The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221102005965\\\/en\\\/1623204\\\/21\\\/AAHI_BrandAssets_PhotonFactory_20211201_AAHI_Logo_Color.jpg\",\"datePublished\":\"2022-11-02T19:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221102005965\\\/en\\\/1623204\\\/21\\\/AAHI_BrandAssets_PhotonFactory_20211201_AAHI_Logo_Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221102005965\\\/en\\\/1623204\\\/21\\\/AAHI_BrandAssets_PhotonFactory_20211201_AAHI_Logo_Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/","og_locale":"en_US","og_type":"article","og_title":"The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature - Pharma Trend","og_description":"SEATTLE–(BUSINESS WIRE)–Today, the Access to Advanced Health Institute (AAHI) announced results from a study of their new RNA vaccine against COVID-19. Preclinical studies published in NPJ Vaccines demonstrate the ability of AAHI\u2019s unique SARS-CoV-2 self-amplifying RNA vaccine to elicit strong antibody and T cell immunity to multiple variants of SARS-CoV-2. This next-generation approach to RNA ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-02T19:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221102005965\/en\/1623204\/21\/AAHI_BrandAssets_PhotonFactory_20211201_AAHI_Logo_Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature","datePublished":"2022-11-02T19:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/"},"wordCount":725,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221102005965\/en\/1623204\/21\/AAHI_BrandAssets_PhotonFactory_20211201_AAHI_Logo_Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/","url":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/","name":"The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221102005965\/en\/1623204\/21\/AAHI_BrandAssets_PhotonFactory_20211201_AAHI_Logo_Color.jpg","datePublished":"2022-11-02T19:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221102005965\/en\/1623204\/21\/AAHI_BrandAssets_PhotonFactory_20211201_AAHI_Logo_Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221102005965\/en\/1623204\/21\/AAHI_BrandAssets_PhotonFactory_20211201_AAHI_Logo_Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/the-access-to-advanced-health-institute-develops-longer-lasting-and-broadly-protective-sars-cov-2-rna-vaccine-candidate-that-is-stable-at-room-temperature\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50407"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50407\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}